Compare ESPR & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESPR | BTX |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.1M | 773.8M |
| IPO Year | 2013 | N/A |
| Metric | ESPR | BTX |
|---|---|---|
| Price | $3.70 | $6.77 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $6.86 | N/A |
| AVG Volume (30 Days) | ★ 7.0M | 938.4K |
| Earning Date | 11-06-2025 | 11-01-2025 |
| Dividend Yield | N/A | ★ 13.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $303,802,000.00 | N/A |
| Revenue This Year | $25.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $0.69 | $5.10 |
| 52 Week High | $4.03 | $8.31 |
| Indicator | ESPR | BTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.61 | 52.33 |
| Support Level | $3.59 | $6.66 |
| Resistance Level | $3.91 | $6.90 |
| Average True Range (ATR) | 0.24 | 0.17 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 77.74 | 82.30 |
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.